Publicaciones en las que colabora con María de Ujue Moreno Zulategui (36)

2023

  1. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides

    JACC: Heart Failure, Vol. 11, Núm. 1, pp. 58-72

2022

  1. Oxidative Stress in Cardiovascular Disease and Comorbidities

    Antioxidants

2020

  1. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

    Nefrologia, Vol. 40, Núm. 3, pp. 223-236

2019

  1. The renal immune-inflammatory component of arterial hypertension: Emerging therapeutic strategies

    Cardiovascular Research, Vol. 115, Núm. 4, pp. 696-698

2017

  1. Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men

    Free Radical Research, Vol. 51, Núm. 4, pp. 389-396

  2. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites

    Scientific Reports, Vol. 7

2014

  1. Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease: A Role for Cardiotrophin-1?

    Hypertension, Vol. 63, Núm. 3, pp. 468-474

2013

  1. A synthetic peptide from transforming growth factor-β1 Type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats

    Antioxidants and Redox Signaling, Vol. 19, Núm. 14, pp. 1607-1618

  2. Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis

    Clinical Science, Vol. 125, Núm. 6, pp. 291-300

2012

  1. Blockade of TGF-β 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats

    Oxidative Medicine and Cellular Longevity

2011

  1. Genetic remodeling and cardiovascular disease

    Oxidative Stress: A Focus on Cardiovascular Disease Pathogenesis (Nova Science Publishers, Inc.), pp. 95-109

  2. HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia

    Cardiovascular Research, Vol. 92, Núm. 2, pp. 247-255

  3. The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes

    Frontiers in Bioscience - Elite, Vol. 3 E, Núm. 4, pp. 1467-1474

2010

  1. CYBA gene variants as biomarkers for coronary artery disease

    Drug News and Perspectives, Vol. 23, Núm. 5, pp. 316-324

  2. Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications

    Journal of Hypertension, Vol. 28, Núm. 9, pp. 1944-1950

  3. Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension

    Journal of Hypertension, Vol. 28, Núm. 11, pp. 2219-2226

2009

  1. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: Potential implication in hypertension

    Clinical Science, Vol. 116, Núm. 3, pp. 233-240

2007

  1. A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension

    Journal of Hypertension, Vol. 25, Núm. 8, pp. 1620-1626

  2. Oxidative stress, endothelial dysfunction and cerebrovascular disease

    Cerebrovascular Diseases

  3. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: Implications for human atherosclerosis

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, Núm. 3, pp. 587-593